Sugi Predict

Sugi Predict / Compounds / SCHEMBL14935915

SCHEMBL14935915

SCHEMBL14935915

N[C@@H](C(=O)O)C(I)c1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CYP2D6 P10635 2/20 0.48
▸ SRC P12931 1/20 0.48
▸ DPP4 P27487 2/20 0.48
▸ LMNA P02545 2/20 0.46
▸ MAPK1 P28482 1/20 0.46
▸ SLC1A2 P43004 4/20 0.46
▸ SLC1A3 P43003 3/20 0.46
▸ SLC1A1 P43005 3/20 0.46
▸ GRM2 Q14416 1/20 0.43
▸ GRM3 Q14832 1/20 0.43
▸ F2 P00734 1/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ CYP1A2 P05177 1/20 0.42
▸ CYP2C9 P11712 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ ALOX5 P09917 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2939473 1.00 CYP2D6 (0.48) CYP2D6SRCDPP4LMNAMAPK1
Methane SCHEMBL5182658 0.98 CYP2D6 (0.46) CYP2D6SRCDPP4LMNAMAPK1
Methane SCHEMBL5182249 0.98 CYP2D6 (0.46) CYP2D6SRCDPP4LMNAMAPK1
SCHEMBL28688103 0.83 TDP1 (0.44) CYP2D6SRCLMNASLC1A2SLC1A3
SCHEMBL3112337 0.83 TDP1 (0.44) CYP2D6SRCLMNASLC1A2SLC1A3
SCHEMBL189878 0.83 TDP1 (0.44) CYP2D6SRCLMNASLC1A2SLC1A3
Iodide SCHEMBL27294834 0.82 TDP1 (0.43) CYP2D6SRCLMNASLC1A2SLC1A3
Methane SCHEMBL20292606 0.82 TDP1 (0.43) CYP2D6SRCLMNASLC1A2SLC1A3
SCHEMBL1614121 0.77 DPP4 (0.67) CYP2D6SRCDPP4LMNAMAPK1
SCHEMBL1614122 0.77 DPP4 (0.67) CYP2D6SRCDPP4LMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 210 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260083834-A1 CsgA-DERIVED NANOSTRUCTURES AND USES THEREOF FOR ANTIGEN DELIVERY TRANSFERT PLUS LP (CA) 2026-03-26 — — US disclosed
US-20250367300-A1 Nanomaterial and Methods of Use Thereof UNIVERSITY OF CONNECTICUT (US) 2025-12-04 — — US disclosed
US-20250302762-A1 NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF UNIVERSITY OF CONNECTICUT (US) 2025-10-02 — — US disclosed
US-20250302971-A1 Therapeutic Nanomaterials UNIV CONNECTICUT (US) 2025-10-02 — — US disclosed
US-20250229081-A1 NANOMATERIAL COATED ELECTRODE AND METHODS OF USE THEREOF UNIVERSITY OF CONNECTICUT 2025-07-17 — — US disclosed
EP-4584301-A1 CSGA-DERIVED NANOSTRUCTURES AND USES THEREOF FOR ANTIGEN DELIVERY Transfert Plus, Limited Partnership (CA) 2025-07-16 — — EP disclosed
EP-4578867-A1 CYCLIC PEPTIDE OR SALT THEREOF AND MDMX INHIBITOR FUJIFILM Corporation (JP) 2025-07-02 — — EP disclosed
EP-4578868-A1 CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR FUJIFILM Corporation (JP) 2025-07-02 — — EP disclosed
CN-120202010-A Ligand-oligonucleotide conjugates and linkers for use therewith 上海京新生物医药有限公司 2025-06-24 — — CN disclosed
US-20250179119-A1 CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR FUJIFILM CORPORATION (JP) 2025-06-05 — — US disclosed
WO-2015153402-A1 PEPTIDE FRAGMENTS OF NETRIN-1 AND COMPOSITIONS AND METHODS THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2015-10-08 — — WO disclosed
US-9096684-B2 Peptidomimetic macrocycles AILERON THERAPEUTICS, INC. (US) 2015-08-04 — — US disclosed
US-20150183825-A1 TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES AILERON THERAPEUTICS, INC. 2015-07-02 — — US disclosed
WO-2015051122-A2 WNT COMPOSITIONS AND METHODS FOR PURIFICATION THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2015-04-09 — — WO disclosed
US-8987414-B2 Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles AILERON THERAPEUTICS, INC. (US) 2015-03-24 — — US disclosed
US-20150051155-A1 PEPTIDOMIMETIC MACROCYCLES HOFFMANN-LA ROCHE, INC. 2015-02-19 — — US disclosed
US-8927500-B2 Peptidomimetic macrocycles AILERON THERAPEUTICS, INC. (US) 2015-01-06 — — US disclosed
US-20130274205-A1 PEPTIDOMIMETIC MACROCYCLES AILERON THERAPEUTICS, INC. 2013-10-17 — — US disclosed
US-20130210745-A1 TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES AILERON THERAPEUTICS, INC. (US) 2013-08-15 — — US disclosed
US-20130123169-A1 PEPTIDOMIMETIC MACROCYCLES AILERON THERAPEUTICS, INC. (US) 2013-05-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250302971-A1 Therapeutic Nanomaterials TIE1, TEKT1, POLRMT CYP2D6 4662/4885SRC 1434/4885DPP4 1357/4885
US-20250179119-A1 CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR MLX, BMX, ADM2 CYP2D6 4861/4885SRC 1191/4885DPP4 1217/4885
US-20250367300-A1 Nanomaterial and Methods of Use Thereof EPCAM, CD47, JAK2 CYP2D6 893/4885SRC 621/4885DPP4 1271/4885
US-20250302762-A1 NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF JAK2, JAK1, CHMP4B CYP2D6 1980/4885SRC 725/4885DPP4 3265/4885
US-20150051155-A1 PEPTIDOMIMETIC MACROCYCLES TP53, MDM2, MDM4 CYP2D6 4613/4885SRC 1188/4885DPP4 2078/4885
US-20260083834-A1 CsgA-DERIVED NANOSTRUCTURES AND USES THEREOF FOR ANTIGEN DELIVERY VSIG8, MICA, CD74 CYP2D6 4548/4885SRC 3967/4885DPP4 3067/4885
US-20130123169-A1 PEPTIDOMIMETIC MACROCYCLES GHRHR, GHSR, GHITM CYP2D6 4688/4885SRC 1532/4885DPP4 265/4885
US-20130210745-A1 TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES IL33, TPR, CDC37 CYP2D6 4191/4885SRC 696/4885DPP4 677/4885
US-20130274205-A1 PEPTIDOMIMETIC MACROCYCLES PROKR1, GLP1R, PROKR2 CYP2D6 4561/4885SRC 733/4885DPP4 128/4885
US-20150183825-A1 TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES IL33, TPR, CDC37 CYP2D6 4191/4885SRC 696/4885DPP4 677/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.